Tumor regression after intravenous administration of targeted vesicles entrapping the vitamin E α-tocotrienol

Reatul Karim, Sukrut Somani, Majed Al Robaian, Margaret Mullin, Rumelo Amor, Gail McConnell, Christine Dufès

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)
38 Downloads (Pure)


The therapeutic potential of tocotrienol, a member of the vitamin E family of compounds with potent in vitro anti-cancer properties, is limited by its inability to specifically reach tumors following intravenous administration. The purpose of this study is to determine whether a novel tumor-targeted vesicular formulation of tocotrienol would suppress the growth of A431 epidermoid carcinoma and B16-F10 melanoma in vitro and in vivo.
In this work, we demonstrated that novel transferrin-bearing multilamellar vesicles entrapping α-T3 resulted in a dramatically improved (by at least 52-fold) therapeutic efficacy in vitro on A431 cell line, compared to the free drug. In addition, the intravenous administration of tocotrienol entrapped in transferrin-bearing vesicles resulted in tumor suppression for 30% of A431 and 60% of B16-F10 tumors, without visible toxicity. Mouse survival was enhanced by more than 13 days compared to controls administered with the drug solution only.
This tumor-targeted, tocotrienol-based nanomedicine therefore significantly improved the therapeutic response in cancer treatment.
Original languageEnglish
Pages (from-to)79-87
Number of pages9
JournalJournal of Controlled Release
Early online date18 Dec 2016
Publication statusPublished - 28 Jan 2017


  • tocotrienol
  • transferrin
  • cancer therapy
  • tumor targeting
  • delivery system
  • anti-cancer
  • vesicular formulation
  • epidermoid carcinoma


Dive into the research topics of 'Tumor regression after intravenous administration of targeted vesicles entrapping the vitamin E α-tocotrienol'. Together they form a unique fingerprint.

Cite this